Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | MC1R | Q01726 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343198 | 1.00 | PYGL (0.41) | PYGLDRD2DRD3HRH3PAK1 | |
| SCHEMBL1343725 | 0.92 | GPR183 (0.41) | PYGLHRH3CCR2GPR183 | |
| SCHEMBL1343722 | 0.92 | GPR183 (0.41) | PYGLHRH3CCR2GPR183 | |
| SCHEMBL1344626 | 0.84 | GPR183 (0.42) | PYGLHRH3CCR2GPR183 | |
| SCHEMBL1344624 | 0.84 | GPR183 (0.42) | PYGLHRH3CCR2GPR183 | |
| SCHEMBL1345065 | 0.84 | GPR183 (0.42) | PYGLHRH3CCR2GPR183 | |
| SCHEMBL1345062 | 0.84 | GPR183 (0.42) | PYGLHRH3CCR2GPR183 | |
| SCHEMBL1344625 | 0.84 | GPR183 (0.42) | PYGLHRH3CCR2GPR183 | |
| SCHEMBL1343943 | 0.83 | GPR183 (0.41) | PYGLHRH3CCR2GPR183 | |
| SCHEMBL1343946 | 0.83 | GPR183 (0.41) | PYGLHRH3CCR2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | PYGL 4073/4885DRD2 448/4885DRD3 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.